Education
About Us
Working with TipRanks
Follow Us
DBV Technologies SA - American (DBVT)
NASDAQ:DBVT
RESEARCH TOOLSreports
DBVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.20 - $8.31
Previous CloseN/A
Volume52.91K
Average Volume (3M)18.03K
Market Cap
$86.59M
Enterprise Value$28.88M
Total Cash (Recent Filing)$141.37M
Total Debt (Recent Filing)$6.55M
Price to Earnings (P/E)―
Beta-0.36
Next Earnings
May 01, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.85
Shares Outstanding20,569,500
10 Day Avg. Volume28,392
30 Day Avg. Volume18,029
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.61
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.84
Enterprise Value/Ebitda-0.29
Forecast
1Y Price Target
$10.00Price Target Upside155.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
DBV Technologies SA - American News
PremiumCompany Announcements
DBV Technologies Reports Positive Phase 3 Study Results
PremiumCompany Announcements
DBV Technologies Amends Executive Severance Agreements---
Bulls Say, Bears Say
Bulls Say
Commercial OpportunityInvestors now have the goal line for Viaskin Peanut in sight, which is relatively derisked, and can start evaluating the commercial opportunity which could be ~$2B+ annually.
Product Efficacy And SafetyViaskin Peanut's efficacy and safety continue to improve over time in 1-3 year olds, with new analysis supporting its proposed labeling approach.
Regulatory ApprovalThe FDA agreed the safety database from the ongoing Phase 3 VITESSE trial in 4-7 year olds will be sufficient for a BLA submission, allowing DBVT to accelerate its BLA submission.
Bears Say
Financial HealthDBVT ended the year with $33M in cash which management said is sufficient to fund operations into April, so management will need to bring in capital immediately.
Operational ChallengesDBVT is shoring up Viaskin Peanut’s development path, with a largely derisked commercial opportunity, especially in the 1-3 year olds.
---
Ownership Overview
0.81% Insiders
0.02% Mutual Funds
10.88% Other Institutional Investors
88.30% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DBVT FAQ
What was DBV Technologies SA - American’s price range in the past 12 months?
DBV Technologies SA - American lowest stock price was $2.20 and its highest was $8.31 in the past 12 months.
What is DBV Technologies SA - American’s market cap?
DBV Technologies SA - American’s market cap is $86.59M.
When is DBV Technologies SA - American’s upcoming earnings report date?
DBV Technologies SA - American’s upcoming earnings report date is May 01, 2025 which is in 33 days.
How were DBV Technologies SA - American’s earnings last quarter?
DBV Technologies SA - American released its earnings results on Mar 24, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.22 by -$0.02.
Is DBV Technologies SA - American overvalued?
According to Wall Street analysts DBV Technologies SA - American’s price is currently Undervalued.
Does DBV Technologies SA - American pay dividends?
DBV Technologies SA - American does not currently pay dividends.
What is DBV Technologies SA - American’s EPS estimate?
DBV Technologies SA - American’s EPS estimate is -0.24.
How many shares outstanding does DBV Technologies SA - American have?
DBV Technologies SA - American has 20,569,500 shares outstanding.
What happened to DBV Technologies SA - American’s price movement after its last earnings report?
DBV Technologies SA - American reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.22. Following the earnings report the stock price went down -10.621%.
Which hedge fund is a major shareholder of DBV Technologies SA - American?
Currently, no hedge funds are holding shares in DBVT
---
DBV Technologies SA - American Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (155.75% Upside)
$10.00 (155.75% Upside)
Hedge Fund Trend
Decreased
By 1.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $510.0 over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-49.00%
12-Months-Change
Fundamentals
Return on Equity
-135.93%
Trailing 12-Months
Asset Growth
-64.10%
Trailing 12-Months
Company Description
DBV Technologies SA - American
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
---
DBVT Stock 12 Month Forecast
Average Price Target
$10.00
▲(155.75% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
VistaGen Therapeutics
―
Seres Therapeutics
―
AnaptysBio
―
Xeris Pharmaceuticals
―
Best Analysts Covering DBVT
1 Year
1 Year Success Rate
7/27 ratings generated profit
1 Year Average Return
-23.95%
reiterated a buy rating 5 days ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 25.93% of your transactions generating a profit, with an average return of -23.95% per trade.
---